Adaptimmune Therapeutics PLC (ADAPY) stock: key figures, P/E, revenue and dividend
Health Care · United Kingdom
Price
0.03 USD
Market cap
8.48 m USD
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–
Adaptimmune Therapeutics PLC financials
| Fiscal year | 2024 |
|---|---|
| Revenue | 178.03 m USD |
| Gross profit | 177.96 m USD |
| Operating income | -68.76 m USD |
| EBIT | -63.89 m USD |
| Net income | -70.81 m USD |
| Diluted EPS – continuing operations | -0.05 USD |
Full history since 2013, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics plc engages in research, development, and subsequent manufacture and commercialisation of cell therapies to treat cancer in the United States and the United Kingdom. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
More stocks
- Enveric Biosciences, Inc. (ENVB)
- ADM ENDEAVORS, INC. (ADMQ)
- LataMed AI Corp. (LMED)
- GAXOS.AI INC. (GXAI)
- Zeo ScientifiX, Inc. (ZEOX)
- Rocky Mountain Chocolate Factory, Inc. (RMCF)
- Stimcell Energetics Inc. (STME)
- Tempest Therapeutics, Inc. (TPST)
- Sky Quarry Inc. (SKYQ)
- Oncotelic Therapeutics, Inc. (OTLC)
- Blue Star Foods Corp. (BSFC)
- Mag Mile Capital, Inc. (MMCP)
Not investment advice. All data without warranty, price as of 17.11.2026. Details in the risk notice.